This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1lmc

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1lmc.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1lmc.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1lmc| PDB=1lmc | SCENE= }}
{{STRUCTURE_1lmc| PDB=1lmc | SCENE= }}
-
'''THE CRYSTAL STRUCTURE OF A COMPLEX BETWEEN BULGECIN, A BACTERIAL METABOLITE, AND LYSOZYME FROM THE RAINBOW TROUT'''
+
===THE CRYSTAL STRUCTURE OF A COMPLEX BETWEEN BULGECIN, A BACTERIAL METABOLITE, AND LYSOZYME FROM THE RAINBOW TROUT===
-
==Overview==
+
<!--
-
Bulgecin, a sulfonated glycopeptide produced by Pseudomonas acidophila and Pseudomonas mesoacidophila, induces bulge formation and enhances lysis of bacterial cell walls when used in combination with beta-lactam antibiotics. The compound does not itself exhibit any antibacterial activity, but has been shown to inhibit a soluble lytic transglycosylase (SLT70) from Escherichia coli which has a lysozyme-like domain. Recently, the crystal structure of an SLT-bulgecin complex has been determined to 3.5 A resolution. We report here the crystal structure of a complex between lysozyme from the rainbow trout (RBTL) and bulgecin A at 2.0 A resolution. As for the SLT-bulgecin complex, bulgecin is bound with the glycosaminyl moiety in subsite C and the proline residue in site D of the active-site cleft of RBTL, where it makes hydrogen-bonding interactions with the catalytic residues. The taurine moiety is bound to the left side of subsites E and F in the lower part of the active-site cleft. From the observed position of the bulgecin molecule, it seems reasonable that it is an inhibitor of rainbow trout lysozyme. The lysozymes may, in general, be a target for the design of a novel type of antibiotics distinct from the beta-lactams which are insensitive to the muramidases.
+
The line below this paragraph, {{ABSTRACT_PUBMED_15299732}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 15299732 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_15299732}}
==About this Structure==
==About this Structure==
Line 25: Line 29:
[[Category: Hough, E.]]
[[Category: Hough, E.]]
[[Category: Karlsen, S.]]
[[Category: Karlsen, S.]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 00:03:46 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jul 2 21:25:21 2008''

Revision as of 18:25, 2 July 2008

Image:1lmc.png

Template:STRUCTURE 1lmc

THE CRYSTAL STRUCTURE OF A COMPLEX BETWEEN BULGECIN, A BACTERIAL METABOLITE, AND LYSOZYME FROM THE RAINBOW TROUT

Template:ABSTRACT PUBMED 15299732

About this Structure

1LMC is a Single protein structure of sequence from Oncorhynchus mykiss. Full crystallographic information is available from OCA.

Reference

Structure of a complex between bulgecin, a bacterial metabolite, and lysozyme from the rainbow trout., Karlsen S, Hough E, Acta Crystallogr D Biol Crystallogr. 1996 Jan 1;52(Pt 1):115-23. PMID:15299732

Page seeded by OCA on Wed Jul 2 21:25:21 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1lmc"
Personal tools